

## Fact Sheet

Name	<b>InfectoPharm Arzneimittel und Consilium GmbH</b>
Sector	Pharmaceutical industry
Type	Family-owned company, now in second generation
Target markets	Pharmaceuticals for children (pediatrics, social pediatrics) Infectiology, dermatology, pneumology, allergology, ENT Special preparations for use in hospitals Over-the-counter (OTC) products for self-medication
Core	Development and continuous improvement of pharmaceuticals with medically proven active ingredients
Guiding principle	"Knowledge is Health"
USP	<i>consilium</i> service – impartial consulting, training and knowledge transfer for physicians and other healthcare professionals in Germany
Headquarter	Heppenheim (Hesse), Germany
Founded in	1988
Founder	Dr. Manfred Zöller† and Monika Zöller
Management Board	Philipp Zöller – Strategy, Business Development Michael Gilster – Business Administration, IT, Logistics Dr. Markus Rudolph – Marketing & Sales, International Business Dr. Aldo Ammendola – Manufacturing, Research & Development
Size:	275 InfectoPharm Germany, 115 Beyvers
Number of employees	Branches: 6 Austria, 26 Italy, 7 France
Revenue	~ 275 mill. euros InfectoPharm Group (2023) ~ 250 mill. euros InfectoPharm Germany (2023)
Annual growth rate	~ 10 %
International	Export to more than 30 countries, main target area is Europe
Products	Over 130, approx. 75 of which are prescription-only pharmaceuticals
Market leader Germany	Pediatrics
Subsidiaries	Pädia GmbH, Heppenheim (OTC products for children) <a href="http://www.paedia.de">www.paedia.de</a>  Beyvers GmbH, Berlin (CMO for liquids and semi-liquids) <a href="http://www.beyvers.de/">www.beyvers.de/</a>

Branches

Vienna, Austria  
[www.infectopharm.at](http://www.infectopharm.at)

Milan, Italy  
[www.infectopharm.it](http://www.infectopharm.it)

Lyon, France

–

Marlow, United Kingdom

–

Awards

1,000 Companies to Inspire Europe (LSEG), Most Crisis-Proof Employer (Creditreform), Golden Tablet, Most Innovative Product, Best Pharmaceutical Company (Pharma Trend Deutschland), Innovator of the Year (Statista & Capital), Germany's Best (Focus Money), Green Champion (F.A.Z.-Institut)

Last update: 05.2024

## About InfectoPharm

InfectoPharm Arzneimittel und Consilium GmbH specializes in the initial and further development of pharmaceuticals. Over the last 35 years, this family-owned German company has established itself as a groundbreaking pioneer in the industry. The portfolio currently comprises about 130 preparations – including numerous innovations in the fields of pediatrics, infectious diseases, pulmonology, dermatology, allergology, and otolaryngology – which are increasingly gaining international recognition. The “*consilium* service” provides impartial consulting and knowledge transfer to healthcare professionals, free of charge.

The InfectoPharm Group has branches in Austria, Italy, the United Kingdom and France, as well as two strategically complementary subsidiaries in Germany: Pädia GmbH with its distinct pediatric OTC portfolio, and Beyvers GmbH as an internationally known full-service supplier for pharmaceuticals and cosmetics. The group has more than 400 employees and posts an annual turnover of approximately 275 million euros (2023), with an average growth rate of 10 percent. InfectoPharm regularly receives awards from the medical community, such as the "Golden Tablet", and from the business sector, for example as the "Most Crisis-Proof Employer", "Most Crisis-Proof Company", and "Most Innovative Company".